CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 30, 2016
Result type: Reports
Project Number: SR0488-000
Product Line: Common Drug Review

Generic Name: Empagliflozin

Brand Name: Jardiance

Manufacturer: Boehringer Ingelheim (Canada) Ltd.

Indications: Diabetes mellitus, type 2 with high cardiovascular risk

Project Status: Complete

Date Recommendation Issued: October 26, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions